Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137774 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumors, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 3
- Study locations
NCT00137774: Completed Phase 2 study of Neuroendocrine Tumors, sponsored by Dana-Farber Cancer Institute.
NCT00137774 is a Phase 2 study of Neuroendocrine Tumors that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 34 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137774, a Phase 2 study of Neuroendocrine Tumors, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Insitute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00137774 record still lists
NCT00137774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00137774 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00137774 about?
NCT00137774 is a clinical study titled "Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors". The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.
What is the current status of trial NCT00137774?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2004-11. Estimated completion is 2012-12.
What conditions does trial NCT00137774 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT00137774?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00137774?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137774 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00137774's enrollment target sits among peer trials
34 36th of 52 higher than 17 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia